Bifogade filer
Beskrivning
Land | Sverige |
---|---|
Lista | Mid Cap Stockholm |
Sektor | Hälsovård |
Industri | Vård & Omsorg |
The members of the Nomination Committee for Humana AB's Annual General Meeting in 2025 have now been appointed.
According to the instructions adopted at the General Meeting Humana AB shall have a Nomination Committee comprising one representative for each of the four principal shareholders in terms of votes and the Chairman of the Board. In the event that a shareholder chooses to refrain representation in the Nomination Committee, if the Nomination Committee deems it appropriate, a representative of the next largest shareholder may be given the opportunity to join.
Based on the ownership structure as of August 31, 2024, the following individuals have been appointed to members of the Nomination Committee for the 2025 Annual General Meeting:- Fredrik Strömholm, representative from Impilo Care AB, Chairman of the Nomination Committee
- Alexander Kopp, representative from Incentive AS
- Anette Andersson, representative from SEB Investment Management AB
- Richard Torgerson, representative from Nordea Funds
- Anders Nyberg, Humana's Chairman of the Board
The Nomination Committee shall prepare proposals for the Annual General Meeting regarding the Chairman of the Annual General Meeting, number of Board members, fees to be paid to each of the Board members, election of Board members and Board Chairman, remuneration to the auditor and election of auditor and, if necessary, proposal for changes in the instruction to the Nomination Committee.
The Annual General Meeting of Humana AB will be held on Tuesday, May 6, 2025.
Shareholders who wish to present proposals to the Nomination Committee for the 2024 Annual General Meeting can submit them through email to arsstamma@humana.se orby post to Humana AB, AGM, Att: Ewelina Pettersson, Warfvinges väg 39, S-112 51 Stockholm. In order for the Nomination Committee to be able to consider submitted proposals in a constructive manner, these should be submitted by 9 January 2025, at the latest.
For more information, please contact:
Ewelina Pettersson, Head of Investor Relations
+46 73 074 79 12, ewelina.pettersson@humana.se